Trogenix Secures $95M Series A Financing to Advance Novel Glioblastoma Therapy into Clinical Trials

October 6,Edinburgh, UK – Trogenix, a leading biotechnology company dedicated to developing innovative cancer therapies, announced the completion£70 million/$95 millionSeries A financing. This funding will enable its robust pipeline of potential therapeutic cancer treatments for multiple aggressive solid tumors to rapidly advance into clinical trials.

Trogenix was founded in 2023Year, based on the co-founderSteve PollardThe professor's groundbreaking research at the University of Edinburgh includes the UK Centre for Mammalian Synthetic Biology, the Institute for Regeneration and Repair, and Cancer Research UK Scotland.Trogenix integrates cutting-edge technologies in genomics, oncology, immunotherapy, and gene therapy to create a revolutionary treatment method through its Odysseus® platform. Using proven AAV vectors, proprietary synthetic super enhancers (SSE) are directly delivered to tumor cells without detection. SSE enables unprecedented precision in gene control, effectively revealing cancer to the human immune system and killing tumor cells.

Trogenix CEO Ken Macnamara said:"This significant investment has accelerated our leading program in glioblastoma and our subsequent program in colorectal cancer liver metastases through clinical trials, advanced our pipeline in liver and lung cancer, and further enhanced our Odysseus® platform. We are honored to have the support of both existing and new investors who share our mission to provide breakthrough treatments and seek cures for the thousands of patients and families facing devastating diagnoses each year."

Series A Financing Led by IQ Capital, with Founding Investor 4BIO Capital, Existing Investors Cancer Research Horizons, BTIF, New Investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital, Alongside Undisclosed Private Investors. This investment highlights the transformative and therapeutic potential of Trogenix's precision genetic medicines, powered by the company’s Odysseus® platform, which identifies and targets universal vulnerabilities in solid tumors. Trogenix’s revolutionary technology delivers highly effective combination payloads that kill cancer cells and stimulate the immune system while leaving surrounding healthy tissue intact, thereby transforming treatment paradigms for cancer patients.

Trogenix Combines Dual Forces of Cancer Cell Killing and Immune Stimulation to Revolutionize Cancer Treatment by Reawakening the Immune System Through a Trojan Horse Approach, Offering Long-Term Protection Against Tumor Recurrence. At the Core of Trogenix’s Precision Cancer Therapy Lies Its Proprietary Synthetic Super Enhancer (SSE), Which Activates Based on Unique Characteristics of Diseased Cell States Rather Than Individual Genes to Control Two Key Payloads: Cytotoxic Prodrug Convertase and Immune-Stimulating Cytokines. SSE Is Meticulously Designed Using Trogenix’s Proprietary Technology Platform Odysseus®, Which Rigorously Identifies and Optimizes Targets Within Cancer Cells to Rapidly Generate Candidates with Manufacturable Features for Preclinical Development.

Trogenix's leading project in glioblastoma (GBM), one of the most aggressive and treatment-resistant brain cancers, is moving toward clinical trials, with the first patient dosing expected in the first quarter of 2026. Only 25% of GBM patients survive beyond one year, and despite decades of research and significant investment, treatment options remain severely limited. The company’s follow-up program focuses on colorectal cancer liver metastasis (CRCLM). Colorectal cancer is the third most common cancer globally, with at least 25% of patients developing CRCLM. In addition to its lead and follow-up programs, Trogenix will also advance its pipeline focused on other aggressive solid cancers, including hepatocellular carcinoma and non-small cell lung cancer.